Swissmedic: Talidox® – A known substance with Innovation

In order to obtain certainty about the applicable regulatory requirements for the registration of TLD-1, InnoMedica has requested a Scientific Advice Meeting with Swissmedic. We are pleased to announce that Swissmedic shares InnoMedica’s assessment of TLD-1 as a known substance with innovation….

In vitro data: Talidox® shows similar cell killing activity compared to free doxorubicin

In vitro data: Talidox® shows similar cell killing activity compared to free doxorubicin

The cell killing activity of 100 μg/ml doxorubicin was measured on human uterine sarcoma cells in vitro in a cytotoxicity study. The cytotoxic effect of 100 μg/ml free doxorubicin (Adriblastin) was compared to 100 μg/ml doxorubicin formulated as Doxil® and 100 μg/ml…

June 2014: Annual general meeting 2014

June 2014: Annual general meeting 2014

The Board of InnoMedica cordially invites all shareholders to attend the Annual General Meeting 2014. The Annual General Meeting will be held on Tuesday, June 24th  2014 at 04:15 pm (doors open at 04:00 pm) in the conference room of the OBC Suisse…

April 2014: Innomedica at swiss Biotech Day 2014

April 2014: Innomedica at swiss Biotech Day 2014

InnoMedica presents itself and the project TLD-1 at the Swiss Biotech Day 2014 at the Kongresshaus in Zurich: short presentation by Jonas Zeller (Financial Controller), direct exchange with the team at the InnoMedica booth (Rollup 1 & Rollup 2).

February 2014: Oversubscribed – Capital increase successful

The capital increase of InnoMedica by 49,000 shares / CHF 655’500 was successfully completed with oversubscription. We are very pleased with the interest in our company as well as our project and want to give the 40 new shareholders a…

february 2014: Support from SAKK

FEBRUARY 2014: SUPPORT FROM SAKK INNOMEDICA RECEIVES SUPPORT FROM THE SAKK InnoMedica and the Swiss Group for Clinical Cancer Research ( SAKK ) hope to gain from the development of new cancer drug TLD -1 improved efficacy and fewer side…

December 2013: Capital increase for current shareholders

Notice to current shareholders concerning ongoing capital increase: Subscription offer of CHF 665,550 / 45,900 bearer shares The subscription period will last until 24 Februar 2014. The subscription price per new share is CHF 14.50 (denomination min. 1,000 shares). English…

September 2013: Production and research laboratories

The InnoMedica establishes the research and production site. For the production of preclinical and initial clinical batches research laboratories in Marly, Fribourg are rented and equipped with the laboratory devices. Production of the first preclinical batch is planned at the…

June 2013: Capital increase successful

In June 2013, InnoMedica was able to complete the Capital Increase approved at the Annual General successfully. The newly acquired capital in the amount of more than CHF 500,000 allows InnoMedica to pursue the establishment of the glucose-based drug-targeting system in…